O uso de inibidores de SGLT 2 no Diabetes Mellitus tipo 1

• Autor(a) principal: ALEOTTI, João Victor Dias
• Data de Publicação: 2021
• Outros Autores: ROCCO JUNIOR, Sidney
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Digital Unicesumar
• Texto Completo: http://rdu.unicesumar.edu.br/handle/123456789/7793
• topic: Inibidores do Transportador 2 de Sódio-Glicose; Diabetes Mellitus Tipo 1; Dapagliflozina; CNPQ::CIENCIAS DA SAUDE::MEDICINA

Diabetes mellitus type 1 is a metabolic disease characterized for the absolute deficiency of insulin, with consequent increase of blood glucose. The current standard treatment is the use of insulin, but its use causes undesirable effects for the patients, like weight gain and hypoglycemia. A new possibility for treatment are the new drugs that inhibits the transporter of sodium and glucose 2. Although this new class of drugs are approved for treatment of diabetes type 2, its use for type 1 is still debatable, with off label indication in Brazil. This kind of drugs lowers the glycated hemoglobin and weight, but there are a small portion of patients that develop euglycemic ketoacidosis and urinary infections. Thus, we reunited sources and studies to revise and compile information about this new drug class in treatment of diabetes mellitus type 1. We conclude that the use of sodium-glucose transporter 2 inhibitors in treatment of diabetes mellitus type 1, specially dapagliflozin, is very promising and its beneficial effects are very superior to its harmful effects that only a small part of patients develops, and that can be easily avoided if both patients and doctors are well informed about the risks of the medication.